Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. (2018). SKIN The Journal of Cutaneous Medicine, 2(S1), S22. https://doi.org/10.25251/skin.2.supp.22